Evaxion A/S · NASDAQ:EVAX
Evaxion A/S — Evaxion Biotech — FY2023 Earnings Presentation
23 slides from Evaxion A/S's earnings presentation, Apr 2, 2024
Slide 1: Evaxion Business Update Conference Call Full Year 2023
Evaxion Business Update Conference Call Full Year 2023 Christian Kanstrup, CEO Birgitte Rønø, CSO Jesper Nyegaard Nissen, COO & CFO April 2, 2024
Slide 2: Agenda
AGENDA 1. Welcome CEO, Christian Kanstrup 2. Corporate Update CEO, Christian Kanstrup 3. R&D/Business Update CSO, Birgitte Rønø 4. 2023 Financial Results COO & CFO, Jesper Nyegaard Nissen 5. Conclusive Remarks CEO, Christian Kanstrup 6. Q&A 2
Slide 3: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “m
Slide 4: Summary
Summary • Refined strategy launched and anchored • Three-pronged business model • Strong progress on financing strategy • Cash into Q1 2025 secured, MSD GHI now largest shareholder • Solid progress on R&D/business strategy • MSD vaccine collaboration reaches key milestone, precision vaccine candidat
Slide 5: Corporate Update
Corporate Update 5
Slide 6: Strategy Recap: Three-Pronged Business Model Based upon AI-Immunology
Strategy Recap: Three-Pronged Business Model Based upon AI-Immunology Multi-partner approach to value realization TARGETS Multi-partner approach focused around single or multiple vaccine target discovery, design and development agreements PIPELINE Own development programs for select high value progr
Slide 7: Strong Progress on Financing Strategy
Strong Progress on Financing Strategy • December 2023: Closed USD 5.3 million private placement • MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & co, USA, welcomed as shareholder • February 2024: Closed USD 15 million (gross) public offering • MSD GHI also participate
Slide 8: R&D/Business Update
R&D/Business Update 8
Slide 9: R&D/Business Update: Pipeline Progress
R&D/Business Update Pipeline Progress Oncology Infection diseases • Strong Initial EVX-01 Phase 2 data • Encouraging results for EVX-B1 vaccine antigens against Staphylococcus aureus • Precision cancer vaccine concept infection developed based on a novel class of tumor antigens • MSD EVX-B3 vaccine
Slide 10: Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology Platform
Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology Platform * 10 *The data generated in the EVX-02 program actively informs the development of the second generation EVX-03 DNA vaccine © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024.
Slide 11: EVX-01 - Phase 2 (NCT05309421)
EVX-01 - Phase 2 (NCT05309421) Personalized neoantigen vaccine in metastatic melanoma Conducted in collaboration with MSD (Merck & Co., Inc) EVX-01 Priming EVX-01 Boosting Production (To activate T-cells) (To maintain level of activated T-cells) Timeline for each W1 W12 W14 W16 W18 W20 W22 W30 W42 W
Slide 12: Encouraging Initial EVX-01 Phase 2 Trial Results
Engouraging Initial EVX-01 Phase 2 Trial Results Response to vaccine neoantigens • Initial data from five patients*: IFNg ELISpot, background subtracted 2000 • Confirm the favorable safety profile of EVX-01 SFUs per 1 x 106 PBMCs 1500 • Neoantigen specific T-cell reactivity induced by EVX-01 detecte
Slide 13: Precision Cancer Vaccine Concept Developed
Precision Cancer Vaccine Concept Developed Based on a novel class of tumor antigens • Precision cancer vaccine concept developed based on a novel class of tumor antigens, named Endogenous Retroviruses, ERVs • This novel vaccine concept allows patient with similar tumor profiles to be treated with th
Slide 14: EVX-B1: Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus aureus Infection
EVX-B1: Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus aureus Infection • Evaxion and its undisclosed collaborator tested Evaxion designed vaccine antigens against Staphylococcus aureus (S. aureus) in a clinically relevant animal model of surgical site infections • The vaccin
Slide 15: EVX-B3: First Milestone Reached in MSD Vaccine Development Collaboration
EVX-B3: First Milestone Reached in MSD Vaccine Development Collaboration • Using Evaxion's proprietary platform, AI-Immunology , Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues • The conclusion of the antigen discovery and design phases marks a
Slide 16: 2023 Financial Results
Yn) = S Y) ® a 5 O Cc fe) = LL o NI oO “I
Slide 17: 2023 Financial Highlights
Financials 2023 Financial Highlights • Cash burn optimized without compromising long-term growth opportunities • External spend and organisation slimmed to reflect focused strategy • As of December 31, 2023, cash and cash equivalents were $5.6 million. • Following the public offering in February 202
Slide 18: 2023 Financial Results (Audited)
Financials 2023 Financial Results (Audited) Evaxion Biotech A/S Consolidated Statement of Comprehensive Loss Data (Audited) • Research and Development (USD in thousands, except per share data) expenses were $11.9 million for Three Months Ended Twelve Months Ended the year ended December 31, 2023 Dec
Slide 19: Conclusive Remarks
Conclusive Remarks 19
Slide 20: Recent Highlights Confirm Strong Strategy Execution
Recent Highlights Confirm Strong Strategy Execution Collaboration with Leading Collaboration with Afrigen Private Placement with Closing of $15 Million Public Pharmaceutical Company Biologics Participation of MSD GHI Offering with Participation MSD GHI OCT-31 NOV-15 DEC-8 JAN-24 FEB-20 SEP-18 SEP-20
Slide 21: Several Important Near-Term Milestones
Several Important Near-Term Milestones Milestones Target EVX-B1 Conclusion of final MTA study with potential partner Q1 2024 AI-Immunology Launch of EDEN model version 5.0 Mid 2024 EVX-B2-mRNA EVX-B2-mRNA preclinical Proof-of-Concept obtained Q3 2024 EVX-01 Phase 2 one-year readout Q3 2024 Conclusio
Slide 22: Q&A
Q&A
Slide 23: Thank you
Thank you